Kimia Pharmaceutical

The production of high-risk drugs(Anticancer drugs)

Profile
Introduction

Kimia Pharmaceutical

Group : Medicine & medical equipment

Company work : The production of high-risk drugs(Anticancer drugs)

Main products : Imatinib Kitent (Sunitinib) Kimotar (Erlotinib) Soranex(Sorafenib) Kimoniَl(Nilotinib)

Novavaran Pharmaceuticals Kimia (Joint Stock) in 2010 with the participation of a number of university professors and specialists in the country's pharmaceutical industry with the aim of creating technical know-how and production of new drugs introduced to the world drug market. The company, including Knowledge Foundation Based in the center of growth of pharmaceutical technology units and Bu'ali National Biotechnology Park, Tehran University of Medical Sciences.

The creation of technical knowledge of pharmaceutical raw materials, the formulation and production of high-risk drugs and special products have been on the agenda since its inception. During the past six years, the company has been able to step through the use of the expertise of domestic experts and the use of trained, innovative and young forces. Has taken a long time to promote the pharmaceutical industry of the country